Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
(5Z)-7-oxozeaenol
- Development stage
- Preclinical
- Modality
- Small Molecules
- Administration
- Intracerebroventricular (experimentally), Not Clinically Established
01
Overview
**(5Z)-7-oxozeaenol** is a resorcylic acid lactone of fungal origin, specifically isolated from *Curvularia* species, and acts as a highly potent, selective, irreversible, and ATP-competitive inhibitor of transforming growth factor-β-activated kinase 1 (TAK1, a MAPKKK). It exhibits strong anti-inflammatory and cytotoxic properties, inhibits the NF-κB signaling pathway, and blocks the production of pro-inflammatory cytokines (IL-17A, IFN-γ, TNF-α, IL-6). It also inhibits other kinases such as VEGF receptor 2 (VEGFR2) and PDGFRβ, but with less potency. (5Z)-7-oxozeaenol has demonstrated efficacy in animal models of CNS autoimmune diseases (such as experimental autoimmune encephalomyelitis, EAE—a model of multiple sclerosis), alleviating symptoms by reducing CNS inflammation, demyelination, and microglial activation[1][3][4][5][6].
- Other names
- (5Z)-7-Oxozeaenol5Z-7-OxozeaenolCHEBI:67559
02
Targets
MAPK3 (Mitogen-activated protein kinase 1)MEK1 (Dual specificity mitogen-activated protein kinase kinase 1)MAP2K7 (Dual specificity mitogen-activated protein kinase kinase 7)TAK1 (Transforming growth factor beta–activated kinase 1)VEGFR2 (Vascular endothelial growth factor receptor 2)NF-κBPDGFRB (Platelet-derived growth factor receptor beta)
Beyond the preview
Go deeper on (5Z)-7-oxozeaenol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on (5Z)-7-oxozeaenol.